Repurposing of marketed / shelved / pipeline candidates for the treatment of diseases (different from original target indications) has emerged as a viable business strategy. The rising popularity of this approach can further be attributed to various benefits, such as reduced development timelines, decreased investments and relatively higher success rates […]